Dasatini-Bona spit monotherapy for adult ph-acute lymphoblastic leukemia.

Since the advent of ABL-specific tyrosine kinase inhibitors, the prognostic prognostics of adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved significantly.
the use of these drugs, whether or not full-body chemotherapy is performed, can provide complete hematological relief to most patients.
the reduction of MRD (minimum residual lesions) was positively associated with an increased chance of cure during ALL treatment.
Based on this, over the past 15 years, the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) team has adopted a chemotherapy-free induction program (applying glucoticoid pretreatment for 7 days), first by centrally evaluating all patients involved in the trial to determine the presence of BCR-ABL1 gene fusion, and then by inducing Ph-positive patients to use tyrosine kinase inhibitors (added corticosteroids).
trials, 94-100% of patients received complete hematological remission and, regardless of age, had few deaths during induction.
the single-group Phase II trial of the experimental team was induced with dual-specific anti-CD3 and anti-CD19 monoclonal antibody Bonatha.
is a second-generation inhibitor of ABL tyrosine kinase, which is more effective than imatinib.
bona spit, a dual-function monoantigen, activates T cells that are resistant to CD3 groups, and on the other hand binds to tumor cells that are resistant to CD19 groups, thus promoting their cytotoxicity.
98 per cent of the 63 patients (with a medium age of 54 years; ranging from 24 to 82 years of age) included in the trial.
at the end of the treatment (day 85), 29 per cent of patients experienced a molecular response, while after two rounds of Bona tantinib therapy, this percentage increased to 60 per cent.
one cycle of bona tactona, and the percentage of patients with molecular reactions increased further.
follow-up for 18 months, the overall survival rate was 95%, and the disease-free survival rate was 88%.
in patients with IKZF1 deficiency plus other genetic distortions (CDKN2A or CDKN2B, PAX5, or both, i.e. IKZF1plus), the survival rate was lower.
during induction therapy, the team detected mutations in ABL1 in six patients with MRD increases, all of which were cleared by Bonatho monoantigen.
six cases of recurrence in the united States.
there were 21 adverse reaction events of level 3 or higher overall.
24 of the patients received allogeneic stem cell transplants, one of which was related to transplantation (4%).
the total survival rate of all patients at the end of induced therapy and after each application of Bonato monoantigen (Figure A), disease-free survival (Figure B) and recurrence (Figure C).
concluded that in this trial, adult Ph-ALL patients could benefit from a chemical-free induction and consolidation programme, starting with dassarinib and then with Bonathadone.
combination of these drugs was associated with a high incidence of complete hematological and molecular responses and an 18-month survival rate.
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults Robin Fo, M.D., Renato Bassan, M.D. October 22, 2020N Engl J Med 2020; 383:1613-1623DOI: 10.1056/NEJMoa2016272 Network Source: Web Copyright Statement: All noted on this website "Source: Mets Medicine" or "" Source: MedSci Originals" text, images and audio and video materials, copyrighted by Metz Medical, are not authorized to be reproduced by any media, website or individual, and must be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.